REG - Verici Dx PLC - Two key patents granted in the US

Verici DxAnnouncement

09/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230309:nRSI3688Sa&default-theme=true

RNS Number : 3688S  Verici Dx PLC  09 March 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

Two key patents for Tutivia™ and Clarava™ granted in the United States

Intellectual property portfolio strengthened

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it has been granted two key patents in the
United States that support and protect the Company's core technologies in RNA
signature biomarker tests used for assessment of the prognostic risk
pre-transplant (Clarava™) and post-transplant (Tutivia™) of acute kidney
transplant rejection.

 

The patents cover broad molecular methods for predicting and diagnosing
subclinical and clinical acute rejection, both pre- and post- kidney
transplant by algorithmic analysis of gene sets and underpin both of Verici
Dx's lead products, Tutivia™ and Clarava™, and provide protection until
2036 and 2039 respectively. The patents underpinning Tutivia™ have also been
previously granted in Europe, China and Australia.

 

These products use a weighted pattern of RNA biomarkers (signature) to assess
the risk of rejection by the kidney transplant recipient and to assess
rejection earlier and more reliably than other currently available methods.
Verici Dx continues to file additional patents reflecting novel refinements to
its predictive RNA signatures and methodologies driven by advanced machine
learning techniques.

 

The protection of the Company's intellectual property is fundamental to its
strategy of amassing full transcriptomic data from the biological systems and
interactions associated with transplant rejection and, over the longer term,
informing transplant analysis in other organs and in the broader field of
immune-mediated diseases.

 

Sara Barrington, CEO of Verici Dx, said:

"Clarava™ and Tutivia™ address a significant unmet need and seek to
improve outcomes for kidney transplant patients, by providing early,
actionable information for clinicians to inform treatment plans. These
significant new patents bolster our intellectual property portfolio and
protect our proprietary methods of predicting and diagnosing sub-clinical and
clinical acute kidney rejection."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 Walbrook PR Limited                                      Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Stephanie Cuthbert /                      Mob: +44 7980 541 893 / +44 7796 794 663 /

 Sam Allen                                                07502 558 258

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

The two lead products are Clarava™, a pre-transplant prognosis test for the
risk of early acute rejection, and Tutivia™, a post-transplant test focused
upon acute cellular rejection, including sub-clinical rejection. These
products seek to measure how a patient is likely to respond, and is
responding, to a kidney transplant. These products are underpinned by
extensive patented and published scientific research from the leading Mount
Sinai Medical Center, for which the Company holds an exclusive worldwide
licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDDGDXGSGDGXI